Pila Pharma - About the company
Pila Pharma is a public company based in Randers (Denmark), founded in 2013 by Dorte Gram. It operates as a Small molecule TRPV1 receptor antagonists for diabetes. Pila Pharma has raised an undisclosed amount in funding. The company has 245 active competitors, including 91 funded and 52 that have exited. Its top competitors include companies like Sana Biotechnology, Adocia and Kailera.
Company Details
Pila Pharma is focussed on developing the tablet-based treatment for diabetes. It is using its patented transient receptor potential cation channel subfamily V member 1 (TrpV1) antagonists for developing its portfolio. Its lead development candidate XEN-D0501 transient receptor potential cation channel subfamily V member 1 (TrpV1) is a highly potent and selective orally available inhibitor of TRPV1 which is currently in clinical development for the treatment of type 2 diabetes.
- Website
- pilapharma.com
- Social
- Email ID
- *****@pilapharma.com
Key Metrics
Founded Year
2013
Location
Randers, Denmark
Stage
Public
Latest Funding Round
Investors
Ranked
138th among 245 active competitors
Employee Count
6 as on Apr 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Pila Pharma
Pila Pharma is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
PILA PHARMA AB CIN: 556966-4831 , Sweden, Active | Mar 25, 2014 | - | - | - |
Pila Pharma Danmark ApS CIN: 39023636 , Denmark, Active | Oct 17, 2017 | - | - |
Sign up to download Pila Pharma's company profile
Pila Pharma's funding and investors
Pila Pharma has raised funding over 3 rounds. Its first funding round was on Feb 27, 2015. Its latest funding round was a Grant (prize money) round on Jul 31, 2019 for $*****. 1 investor participated in its latest round. Pila Pharma has 3 institutional investors.
Here is the list of recent funding rounds of Pila Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 31, 2019 | 5823777 | Grant (prize money) | 2473327 | 3723083 | 6034408 | 3209026 |
Feb 01, 2019 | 2388094 | Grant (prize money) | 5114456 | 3874419 | 7645584 | |
Feb 27, 2015 | 1083298 | Seed | 2653146 | 5935023 | 5899369 |
Access funding benchmarks and valuations. Sign up today!View details of Pila Pharma's funding rounds and investors
Pila Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Pila Pharma is Dorte Gram.
Here are the details of Pila Pharma's key team members:
- Dorte Gram: CSO, Chairman of the Board and Founder in Pila Pharma AB of Pila Pharma.
View details of Pila Pharma's Founder profiles and Board Members
Pila Pharma's employee count trend
Pila Pharma has 6 employees as of Apr 26. Here is Pila Pharma's employee count trend over the years:
Uncover Pila Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Pila Pharma's Competitors and alternates
Top competitors of Pila Pharma include Sana Biotechnology, Adocia and Kailera. Here is the list of Top 10 competitors of Pila Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating human disease conditions | $821M | 75/100 | |
2nd | Developer of therapeutics for the treatment of diabetes and obesity | $26M | 69/100 | ||
3rd | Kailera 2024, Waltham (United States), Public | Developer of therapies for treating obesity and related conditions | $1B | 65/100 | |
4th | Cellino 2017, Cambridge (United States), Series A | Developer of autologous cell therapies | $125M | 65/100 | |
5th |  Quell 2019, London (United Kingdom), Series B | Developer of engineered regulatory T cell therapies for immune diseases | $344M | 65/100 | |
6th | Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public | Developer of small molecule drugs for diffrent health diseases | - | 64/100 | |
7th | Rezolute 2012, Denver (United States), Public | Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI) | - | 64/100 | |
8th | _1568087563364.png?devicePixelRatio=2&height=30&width=30){kind=logo} Veralox Therapeutics 2017, Frederick (United States), Series B | Developer of small molecules for treating thrombosis and diabetes pathologies | $47.5M | 63/100 | |
9th |  Kriya Therapeutics 2012, Redwood City (United States), Series D | Developer of therapeutic solutions for the treatment of diabetes | $938M | 62/100 | |
10th | Akston Biosciences 2011, Beverly (United States), Series B | Developer of therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long-acting insulin therapy, and oncology | $13.8M | 61/100 | |
138th | Pila Pharma 2013, Randers (Denmark), Public | Small molecule TRPV1 receptor antagonists for diabetes | - | 29/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Pila Pharma's competitors? Click here to see the top ones
Pila Pharma's Investments and acquisitions
Pila Pharma has made no investments or acquisitions yet.
News related to Pila Pharma
•
•
Almac Group and Pila Pharma Sign Manufacturing AgreementPharmtech•Aug 14, 2021•Almac Group, Pila Pharma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Pila Pharma
Explore our recently published companies
- Theaiparagonconsulting - Unfunded company
- Thorncapstead Shop - Unfunded company
- Dashlexapro300 - Unfunded company
- Trysuperpower - Unfunded company
- Ashvamedhaai - Unfunded company
- Dzemat-Sabah - 2008 founded, Unfunded company
